Eupraxia Pharmaceuticals (EPRX) Net Income towards Common Stockholders (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has reported Net Income towards Common Stockholders for 4 consecutive years, with -$12.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 87.0% year-over-year to -$12.7 million; the TTM figure through Mar 2026 stood at -$44.5 million (down 68.79% YoY), while the FY2025 annual figure was -$38.6 million, down 49.96% from the prior year.
• Net Income towards Common Stockholders advanced to -$12.7 million in Q1 2026 per EPRX's latest filing, from -$16.7 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$4.0 million in Q1 2023 and bottomed at -$16.7 million in Q4 2025.
• Historically, Net Income towards Common Stockholders has averaged -$7.9 million across 4 years, with a median of -$6.6 million in 2025.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 36.21% — and 2025, when it slumped 121.9%.
• Eupraxia Pharmaceuticals' Net Income towards Common Stockholders stood at -$4.9 million in 2023, then sank by 53.81% to -$7.5 million in 2024, then slumped by 121.9% to -$16.7 million in 2025, then gained by 24.27% to -$12.7 million in 2026.
• Business Quant data shows EPRX's Net Income towards Common Stockholders at -$12.7 million in Q1 2026, -$16.7 million in Q4 2025, and -$6.4 million in Q3 2025.